New Data Shows Eli Lilly and Company's ACTOS(R) (pioglitazone HCl) Reduced Heart Attacks By 28 Percent In People With Type 2 Diabetes

DALLAS, TX -- (MARKET WIRE) -- 11/16/2005 -- New results from secondary analyses of the landmark PROactive Study found that ACTOS® (pioglitazone HCl) significantly reduced the occurrence of fatal and non-fatal heart attacks and acute coronary syndrome (ACS) in high-risk patients with type 2 diabetes who had a previous heart attack. Importantly, these results were above and beyond those seen with standard of care treatment. The findings, which were revealed today at the American Heart Association's Scientific Sessions 2005, build on previously-reported results from the PROactive Study, showing that ACTOS, an oral antidiabetic medication, significantly reduced the combined risk of heart attacks, strokes and death by 16 percent in high-risk patients with type 2 diabetes.

Back to news